PD-1 coinhibitory signals: The link between pathogenesis and protection

Seminars in Immunology

Volumn 25, Issue 3, 2013, Pages 219-227

  Kulpa, Deanna A ^a   Lawani, Mariam ^a   Cooper, Anthony ^a   Peretz, Yoav ^b   Ahlers, Jeff ^a   Sékaly, Rafick Pierre ^a  

^a Vaccine and Gene Therapy Institute Florida (VGTI FL)   (United States)

^b Caprion/ImmuneCarta Services   (Canada)

Author keywords

PD 1 coinhibitory signals

Indexed keywords

INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HEMATOPOIETIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION; VIRUS LOAD;

PD-1 COINHIBITORY SIGNALS;

ANIMALS; BIOLOGICAL MARKERS; HIV INFECTIONS; HUMANS; IMMUNE EVASION; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 84887614931     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.02.002     Document Type: Review

References (116)

1. Blattman J.N., Wherry E.J., Ha S.J., van der Most R.G., Ahmed R. Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. Journal of Virology 2009, 83(May):4386-4394.
2. Fehr T., Lucas C.L., Kurtz J., Onoe T., Zhao G., Hogan T., et al. A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. Blood 2010, 115(February):1280-1287.
3. Patsoukis N., Brown J., Petkova V., Liu F., Li L., Boussiotis V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Science Signaling 2012, 5(June):ra46.
4. Wells A.D. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. Journal of Immunology 2009, 182(June):7331-7341.
5. Phadwal K., Alegre-Abarrategui J., Watson A.S., Pike L., Anbalagan S., Hammond E.M., et al. A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells. Autophagy 2012, 8(April):677-689.
6. Bengsch B., Seigel B., Ruhl M., Timm J., Kuntz M., Blum H.E., et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathogens 2010, 6:e1000947.
7. Lucas C.L., Workman C.J., Beyaz S., LoCascio S., Zhao G., Vignali D.A., et al. LAG-3, TGF-beta, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood 2011, 117(May):5532-5540.
8. Paterson A.M., Brown K.E., Keir M.E., Vanguri V.K., Riella L.V., Chandraker A., et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. Journal of Immunology 2011, 187(August):1097-1105.
9. Yang J., Riella L.V., Chock S., Liu T., Zhao X., Yuan X., et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. Journal of Immunology 2011, 187(August):1113-1119.
10. Kawamoto S., Tran T.H., Maruya M., Suzuki K., Doi Y., Tsutsui Y., et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 2012, 336(April):485-489.
11. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(February):682-687.
12. Kaufmann D.E., Kavanagh D.G., Pereyra F., Zaunders J.J., Mackey E.W., Miura T., et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nature Immunology 2007, 8(November):1246-1254.
13. Lazar-Molnar E., Chen B., Sweeney K.A., Wang E.J., Liu W., Lin J., et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(July):13402-13407.
14. Lee L.F., Logronio K., Tu G.H., Zhai W., Ni I., Mei L., et al. Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(July):12674-12679.
15. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(May):710-722.
16. Okazaki T., Honjo T. Rejuvenating exhausted T cells during chronic viral infection. Cell 2006, 124(February):459-461.
17. Penaranda C., Kuswanto W., Hofmann J., Kenefeck R., Narendran P., Walker L.S., et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(July):12668-12673.
18. Periasamy S., Dhiman R., Barnes P.F., Paidipally P., Tvinnereim A., Bandaru A., et al. Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with Mycobacterium tuberculosis. The Journal of Infectious Diseases 2011, 203(May):1256-1263.
19. Iwai Y., Terawaki S., Ikegawa M., Okazaki T., Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. The Journal of Experimental Medicine 2003, 198(July):39-50.
20. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. Journal of Immunology 2009, 182(May):5891-5897.
21. Trautmann L., Janbazian L., Chomont N., Said E.A., Gimmig S., Bessette B., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine 2006, 12(October):1198-1202.
22. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(June):4781-4789.
23. Fuller M.J., Zajac A.J. Ablation of CD8 and CD4 T cell responses by high viral loads. Journal of Immunology 2003, 170(January):477-486.
24. Shin H., Wherry E.J. CD8 T cell dysfunction during chronic viral infection. Current Opinion in Immunology 2007, 19(August):408-415.
25. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. Journal of Virology 2003, 77(April):4911-4927.
26. Angelosanto J.M., Blackburn S.D., Crawford A., Wherry E.J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. Journal of Virology 2012, 86(August):8161-8170.
27. Radziewicz H., Ibegbu C.C., Fernandez M.L., Workowski K.A., Obideen K., Wehbi M., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. Journal of Virology 2007, 81(March):2545-2553.
28. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. Journal of Immunology 2002, 169(September):3447-3458.
29. Rehermann B., Chang K.M., McHutchinson J., Kokka R., Houghton M., Rice C.M., et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. Journal of Virology 1996, 70(October):7092-7102.
30. Petrovas C., Price D.A., Mattapallil J., Ambrozak D.R., Geldmacher C., Cecchinato V., et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007, 110(August):928-936.
31. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. The Journal of Experimental Medicine 2000, 192(July):63-75.
32. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410(March):106-111.
33. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. The Journal of Experimental Medicine 2003, 198(December):1909-1922.
34. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine 1999, 5(June):677-685.
35. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443(September):350-354.
36. Trautmann L., Mbitikon-Kobo F.M., Goulet J.P., Peretz Y., Shi Y., Van Grevenynghe J., et al. Profound metabolic, functional and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 2012, (September).
37. Gottschalk R.A., Hathorn M.M., Beuneu H., Corse E., Dustin M.L., Altan-Bonnet G., et al. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(January):881-886.
38. Whittall T., Peters B., Rahman D., Kingsley C.I., Vaughan R., Lehner T. Immunogenic and tolerogenic signatures in human immunodeficiency virus (HIV)-infected controllers compared with progressors and a conversion strategy of virus control. Clinical and Experimental Immunology 2011, 166(November):208-217.
39. Cumont M.C., Monceaux V., Viollet L., Lay S., Parker R., Hurtrel B., et al. TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death and Differentiation 2007, 14(October):1747-1758.
40. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews 2010, 236(July):219-242.
41. El-Far M., Halwani R., Said E., Trautmann L., Doroudchi M., Janbazian L., et al. T-cell exhaustion in HIV infection. Current HIV/AIDS Reports 2008, 5(February):13-19.
42. Golden-Mason L., Palmer B., Klarquist J., Mengshol J.A., Castelblanco N., Rosen H.R. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. Journal of Virology 2007, 81(September):9249-9258.
43. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 2008, 26:677-704.
44. Nilsson J., Boasso A., Velilla P.A., Zhang R., Vaccari M., Franchini G., et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006, 108(December):3808-3817.
45. Conrad J.A., Ramalingam R.K., Smith R.M., Barnett L., Lorey S.L., Wei J., et al. Dominant clonotypes within HIV-specific T cell responses are programmed death-1high and CD127low and display reduced variant cross-reactivity. Journal of Immunology 2011, 186(June):6871-6885.
46. Salisch N.C., Kaufmann D.E., Awad A.S., Reeves R.K., Tighe D.P., Li Y., et al. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. Journal of Immunology 2010, 184(January):476-487.
47. Kinter A.L., Godbout E.J., McNally J.P., Sereti I., Roby G.A., O'Shea M.A., et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. Journal of Immunology 2008, 181(November):6738-6746.
48. Forler D., Kocher T., Rode M., Gentzel M., Izaurralde E., Wilm M. An efficient protein complex purification method for functional proteomics in higher eukaryotes. Nature Biotechnology 2003, 21:89-92.
49. Rosignoli G., Cranage A., Burton C., Nelson M., Steel A., Gazzard B., et al. Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. AIDS 2007, 21(June):1379-1381.
50. Rosignoli G., Lim C.H., Bower M., Gotch F., Imami N. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clinical and Experimental Immunology 2009, 157(July):90-97.
51. Koizumi H., Hashimoto M., Fujiwara M., Murakoshi H., Chikata T., Borghan M.A., et al. Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. Journal of Virology 2010, 84(June):5508-5519.
52. Said E.A., Dupuy F.P., Trautmann L., Zhang Y., Shi Y., El-Far M., et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nature Medicine 2010, 16(April):452-459.
53. Ha S.J., West E.E., Araki K., Smith K.A., Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunological Reviews 2008, 223(June):317-333.
54. Zimmerli S.C., Harari A., Cellerai C., Vallelian F., Bart P.A., Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(May):7239-7244.
55. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nature Immunology 2002, 3(November):1061-1068.
56. Rueda C.M., Velilla P.A., Chougnet C.A., Montoya C.J., Rugeles M.T. HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS ONE 2012, 7:e30307.
57. Marchetti G., Bellistri G.M., Borghi E., Tincati C., Ferramosca S., La Francesca M., et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008, 22(October):2035-2038.
58. Jiang W., Lederman M.M., Hunt P., Sieg S.F., Haley K., Rodriguez B., et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. The Journal of Infectious Diseases 2009, 199(April):1177-1185.
59. Che K.F., Shankar E.M., Muthu S., Zandi S., Sigvardsson M., Hinkula J., et al. P38MAPK/STAT3 pathway signaling regulates expression of inhibitory molecules in T-cells activated by HIV-1 exposed dendritic cells. Molecular Medicine 2012, 18(July):1169-1182.
60. Peretz Y., He Z., Shi Y., Yassine-Diab B., Goulet J.P., Bordi R., et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathogens 2012, 8(August):e1002840.
61. Shankar E.M., Che K.F., Messmer D., Lifson J.D., Larsson M. Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells. Molecular Medicine 2011, 17(March-April):229-240.
62. Porichis F., Kwon D.S., Zupkosky J., Tighe D.P., McMullen A., Brockman M.A., et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011, 118(July):965-974.
63. Yamamoto T., Price D.A., Casazza J.P., Ferrari G., Nason M., Chattopadhyay P.K., et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 2011, 117(May):4805-4815.
64. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine 2010, 207(September):2175-2186.
65. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology 2009, 10(January):29-37.
66. Kao C., Oestreich K.J., Paley M.A., Crawford A., Angelosanto J.M., Ali M.A., et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nature Immunology 2011, 12(July):663-671.
67. Lichterfeld M., Mou D., Cung T.D., Williams K.L., Waring M.T., Huang J., et al. Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 2008, 112(November):3679-3687.
68. Lichterfeld M., Kaufmann D.E., Yu X.G., Mui S.K., Addo M.M., Johnston M.N., et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. The Journal of Experimental Medicine 2004, 200(September):701-712.
69. Lichterfeld M., Cung T., Seiss K., Rosenberg E.S., Pereyra F., Yu X.G. Shelterin dysfunction and p16(INK4a)-mediated growth inhibition in HIV-1-specific CD8 T cells. Journal of Virology 2012, 86(May):5533-5540.
70. Palm W., de Lange T. How shelterin protects mammalian telomeres. Annual Review of Genetics 2008, 42:301-334.
71. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes & Development 2005, 19(September):2100-2110.
72. Dimitrova N., de Lange T. MDC1 accelerates nonhomologous end-joining of dysfunctional telomeres. Genes & Development 2006, 20(December):3238-3243.
73. van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998, 92(February):401-413.
74. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458(March):206-210.
75. Sheppard K.A., Fitz L.J., Lee J.M., Benander C., George J.A., Wooters J., et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Letters 2004, 574(September):37-41.
76. Karwacz K., Bricogne C., MacDonald D., Arce F., Bennett C.L., Collins M., et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Molecular Medicine 2011, 3(October):581-592.
77. Vang T., Liu W.H., Delacroix L., Wu S., Vasile S., Dahl R., et al. LYP inhibits T-cell activation when dissociated from CSK. Nature Chemical Biology 2012, 8(May):437-446.
78. Riley J.L. PD-1 signaling in primary T cells. Immunological Reviews 2009, 229(May):114-125.
79. Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(November):13866-13871.
80. Straus D.B., Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992, 70(August):585-593.
81. Davis S.J., van der Merwe P.A. Lck and the nature of the T cell receptor trigger. Trends in Immunology 2011, 32(January):1-5.
82. Schoenborn J.R., Tan Y.X., Zhang C., Shokat K.M., Weiss A. Feedback circuits monitor and adjust basal Lck-dependent events in T cell receptor signaling. Science Signaling 2011, 4(September):ra59.
83. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., Riley J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of Immunology 2004, 173(July):945-954.
84. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2001, 2(March):261-268.
85. Wang S.F., Fouquet S., Chapon M., Salmon H., Regnier F., Labroquere K., et al. Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS ONE 2011, 6:e17621.
86. Brockdorff J., Williams S., Couture C., Mustelin T. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1. European Journal of Immunology 1999, 29(August):2539-2550.
87. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of Experimental Medicine 2012, 209(June):1201-1217.
88. Kwon J., Qu C.K., Maeng J.S., Falahati R., Lee C., Williams M.S. Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP. EMBO Journal 2005, 24(July):2331-2341.
89. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology 2005, 25(November):9543-9553.
90. Henson S.M., Macaulay R., Franzese O., Akbar A.N. Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade. Immunology 2012, 135(April):355-363.
91. Guo H., Qiao G., Ying H., Li Z., Zhao Y., Liang Y., et al. E3 ubiquitin ligase Cbl-b regulates Pten via Nedd4 in T cells independently of its ubiquitin ligase activity. Cell Reports 2012, 1(May):472-482.
92. Quigley M., Pereyra F., Nilsson B., Porichis F., Fonseca C., Eichbaum Q., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nature Medicine 2010, 16(October):1147-1151.
93. Ise W., Kohyama M., Schraml B.U., Zhang T., Schwer B., Basu U., et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nature Immunology 2011, 12(June):536-543.
94. Pepper M., Pagan A.J., Igyarto B.Z., Taylor J.J., Jenkins M.K. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity 2011, 35(October):583-595.
95. Nurieva R.I., Chung Y., Martinez G.J., Yang X.O., Tanaka S., Matskevitch T.D., et al. Bcl6 mediates the development of T follicular helper cells. Science 2009, 325(August):1001-1005.
96. Kroenke M.A., Eto D., Locci M., Cho M., Davidson T., Haddad E.K., et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. Journal of Immunology 2012, 188(April):3734-3744.
97. Duraiswamy J., Ibegbu C.C., Masopust D., Miller J.D., Araki K., Doho G.H., et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. Journal of Immunology 2011, 186(April):4200-4212.
98. Nakamoto N., Kaplan D.E., Coleclough J., Li Y., Valiga M.E., Kaminski M., et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008, 134(June):1927-1937. 1937.e1-2.
99. Doering T.A., Crawford A., Angelosanto J.M., Paley M.A., Ziegler C.G., Wherry E.J. Network analysis reveals centrally connected genes and pathways involved in CD8(+) T cell exhaustion versus memory. Immunity 2012, 37(November):1130-1144.
100. Peretz Y., Cameron C., Sekaly R.P. Dissecting the HIV-specific immune response: a systems biology approach. Current Opinion in HIV and AIDS 2012, 7(January):17-23.
101. Khatri P., Sirota M., Butte A.J. Ten years of pathway analysis: current approaches and outstanding challenges. PLOS Computational Biology 2012, 8:e1002375.
102. Huynh-Thu V.A., Irrthum A., Wehenkel L., Geurts P. Inferring regulatory networks from expression data using tree-based methods. PLoS ONE 2010, 5:e12776.
103. Le Cao K.A., Martin P.G., Robert-Granie C., Besse P. Sparse canonical methods for biological data integration: application to a cross-platform study. BMC Bioinformatics 2009, 10:34.
104. Le Cao K.A., Gonzalez I., Dejean S. integrOmics: an R package to unravel relationships between two omics datasets. Bioinformatics 2009, 25(November):2855-2856.
105. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. Journal of Virology 2007, 81(April):4215-4225.
106. Golden-Mason L., Klarquist J., Wahed A.S., Rosen H.R. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. Journal of Immunology 2008, 180(March):3637-3641.
107. Boettler T., Panther E., Bengsch B., Nazarova N., Spangenberg H.C., Blum H.E., et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. Journal of Virology 2006, 80(April):3532-3540.
108. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. The Journal of Experimental Medicine 2006, 203(October):2281-2292.
109. Titanji K., Velu V., Chennareddi L., Vijay-Kumar M., Gewirtz A.T., Freeman G.J., et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. The Journal of Clinical Investigation 2010, 120(November):3878-3890.
110. Dyavar Shetty R., Velu V., Titanji K., Bosinger S.E., Freeman G.J., Silvestri G., et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. The Journal of Clinical Investigation 2012, 122(May):1712-1716.
111. Janbazian L., Price D.A., Canderan G., Filali-Mouhim A., Asher T.E., Ambrozak D.R., et al. Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. Journal of Immunology 2012, 188(February):1156-1167.
112. Shan L., Deng K., Shroff N.S., Durand C.M., Rabi S.A., Yang H.C., et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36(March):491-501.
113. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine 2012, 366(June):2455-2465.
114. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366(June):2443-2454.
115. Pilon-Thomas S., Mackay A., Vohra N., Mule J.J. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. Journal of Immunology 2010, 184(April):3442-3449.
116. Yu P., Steel J.C., Zhang M., Morris J.C., Waldmann T.A. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clinical cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16(December):6019-6028.